Quantitative measurement of anti-TSH receptor antibodies is useful for the evaluation of treatment effect.

[1]  A. Pinchera,et al.  Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  W. Scherbaum,et al.  Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[3]  C. Chapman,et al.  Measurement of thyroid-stimulating hormone receptor autoantibodies by ELISA. , 1999, Clinical chemistry.

[4]  K. Usadel,et al.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  R. Carson,et al.  Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. , 1992, The Journal of clinical investigation.

[6]  V. Marks,et al.  INAPPROPRIATELY ELEVATED PLASMA INSULIN‐LIKE GROWTH FACTOR II IN RELATION TO SUPPRESSED INSULIN‐LIKE GROWTH FACTOR I IN THE DIAGNOSIS OF NON‐ISLET CELL TUMOUR HYPOGLYCAEMIA , 1990, Clinical endocrinology.

[7]  N. Amino,et al.  On standardization of the radioreceptor assay for anti-thyrotropin receptor antibody. , 1988, Clinical chemistry.

[8]  D. Schoenfeld,et al.  A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.

[9]  B. Smith,et al.  THYROID-STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASE , 1974 .